Servier

Founded 70 years ago to serve health, Servier is an international pharmaceutical group governed by a Foundation, aiming to make a significant societal impact for patients and a sustainable world. Its unique governance model ensures independence and allows it to fully pursue its mission with a long-term vision: to be committed to therapeutic progress for the benefit of patients. The Group’s employees are united around this common purpose, which inspires their daily work.

A global leader in cardiometabolism and venous diseases, Servier has made a major strategic shift toward oncology, which now represents a new pillar of growth. The Group dedicates nearly 70% of its R&D budget to this area, with the ambition of becoming a focused and innovative player in developing treatments for rare cancers. Neurology represents a future growth avenue. In this field, Servier concentrates on a limited number of diseases where precise patient characterization allows for targeted therapeutic responses through precision medicine. To promote access to quality care for all at a lower cost, the Group also offers a portfolio of generic medicines covering most pathologies, leveraging strong brands in France, Eastern Europe, and Brazil. Across all these areas, the Group incorporates the patient’s voice at every stage of the drug lifecycle.

Headquartered in France, Servier relies on dedicated teams and a strong geographic presence, with medicines available in nearly 140 countries. The Group generated €5.9 billion in revenue in 2023/2024 and €1.3 billion in EBITDA (22.2%) in 2024. It currently employs over 22,000 people worldwide.